GFAP and Alzheimer disease: An abnormal accumulation of citrullinated GFAP, mainly in R270, R406, and R416 sites (Fig. 1), was found in hippocampal brain samples of AD patients, demonstrating its significance as a biomarker of neurodegeneration [180, 181].